• 出版社/出版日：Mordor Intelligence / 2020年4月20日
|Single User||￥446,250 (USD4,250)||▷ お問い合わせ|
|Team User||￥498,750 (USD4,750)||▷ お問い合わせ|
|Corporate License||￥787,500 (USD7,500)||▷ お問い合わせ|
The global cytotoxic drugs market size is expected to grow at a CAGR of 1.2% over the forecast period. The availability of novel drugs, presence of strong pipeline, and supportive government legislation for disease awareness are among the key trends in escalating market growth. Besides this, the growing incidence of cancer coupled with increasing geriatric population and unorganized lifestyle is estimated to provide a fillip to the market. As per the World Health Organization, cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. Treatment of cancer majorly includes chemotherapy that involves the use of cytotoxic drugs to inhibit cell division. The increasing number of chemotherapy procedures being performed due to rising cases of cancer is expected to increase the demand for cytotoxic drugs, which will drive the market.
The future of the cytotoxic drugs market has a high probability of gaining an array of novel therapies, with multiple first-in-class developments in each major target family, broadening the scope of potential benefits for patients. The R&D spending from companies like Johnson & Johnson Services, Inc, Eli Lilly and Company, Pfizer, Inc., Mylan N.V, has increased exponentially.
The wide range of pipeline drugs possessing high probability of approval in clinical trials in the future is predicted to provide lucrative growth opportunities to cytotoxic drugs market. For instance, AstraZeneca collaborated with Parexel for the development of novel drug with combination of cytotoxic chemotherapy and AZD7648 so as to treat advanced malignancies. Thus, anticipated to drive the growth of the market.
However, complications associated with cytotoxic drugs and high cost of these drugs may lead to a steep decrease for the market.
Key Market Trends
The Breast Cancer Segment Is Anticipated To Expand At The Fastest CAGR And Is Expected To Continue The Same During The Forecast Period
– Breast cancer is expected to grow at a lucrative CAGR during the forecast period. Rising prevalence of the disease along with emerging novel therapies are some of the major factors likely to drive the segment. According to the World Health Organization, in 2018, breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women.
– The high growth potential attained is a consequence of upsurge in the patient pool suffering from breast cancer. This can be attributed to a significant increase in the demand of cytotoxic drugs.
– Initiatives undertaken by various organizations to create awareness, educate people, and raise funds for the disease is anticipated to propel the segmental growth. For instance, the Ministry of Health and Family Welfare runs the breast cancer awareness month Campaign and educate people about breast cancer. This is likely to propel the growth of the segment thereby increasing the demand for cytotoxic drugs.
The North America Dominates the Market and is Expected to Continue the Same during the Forecast Period
Increasing awareness and presence of established R&D infrastructure are among the key factors contributing to the growth of the market in North America. Moreover, the presence of key players such as Pfizer, Johnson & Johnson, and Fresenius Kabi AG in the region is expected to drive the growth. Rising awareness about the benefits of early detection of cancer has driven the U.S.-based companies to make considerable investments in the development of targeted therapy drugs.
Asia Pacific is anticipated to expand at the fastest CAGR during the forecast period. Rapid growth in global demand for drugs has encouraged major drug manufacturers to set up facilities for manufacturing and R&D in this region. Initiatives undertaken by various organizations to create awareness, educate people, and raise funds for the disease is anticipated to propel regional growth.
The cytotoxic drugs market is moderately competitive and consists of local as well as global players. The major players include companies such as Teva Pharmaceuticals USA, Inc, Cipla Ltd, Mylan N.V., Pfizer Inc., Johnson & Johnson, Fresenius Kabi AG.
Growing collaborations, product differentiation, and initiatives for increasing awareness about cancer treatment are some of the key strategies adopted by these companies to maintain their market position. For instance, in December 2019, Johnson & Johnson runs the financial assistance programs available for DOXIL used in the treatment of cancer that provide free or low-cost health coverage to patients. This was carried out to expand the treatment options and gain a competitive advantage.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Incidence of Target Disease
4.2.2 Supportive Government Legislation
4.2.3 Strong R&D Initiatives from Key Players
4.3 Market Restraints
4.3.1 Complications Associated with Cytotoxic Drugs
4.3.2 High Cost of Cytotoxic Cancer Drugs
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Route of Administration
5.2 By Drug Type
5.2.1 Alkylating Agents
5.2.2 Antitumor Antibiotics
5.2.4 Plant Alkaloids
5.3 By Application
5.3.1 Breast Cancer
5.3.2 Prostate Cancer
5.3.3 Lung Cancer
5.3.4 Pancreatic Cancer
5.4.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle-East and Africa
5.4.5 South America
126.96.36.199 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Baxter Healthcare Corporation
6.1.2 Cipla Ltd
6.1.3 Eli Lilly and Company
6.1.4 Fresenius Kabi AG
6.1.5 Johnson & Johnson
6.1.6 Mylan N.V.
6.1.8 Pfizer Inc.
6.1.9 Sun Pharmaceuticals
6.1.10 Teva Pharmaceuticals USA, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS